Advancing Vaccine Adjuvant Research for Tuberculosis (AVAR-T)

A successful tuberculosis (TB) vaccine would have a major impact on morbidity and mortality associated with TB, and on global TB control. However vaccine strategies have fallen short due to limited understanding of the types of Mycobacterium tuberculosis (Mtb) immunogens that induce long-term protective immunity. The design of an efficacious TB vaccine will also likely require formulation with appropriate vaccine adjuvants. Adjuvants not only induce potent immune responses that cannot be obtained with immunogens alone but are also responsible for driving distinct immune profiles that may be associated with protection against disease.

Data generated from AVAR-T studies will be made publicly available through the Vaccine Adjuvant Compendium (VAC), enabling the rational selection of adjuvants and the future development of more effective vaccines.

Main Areas of Focus

  • To further the development of preventive, including postexposure, TB vaccines through side-by-side comparisons of adjuvants in combination with Mtb immunogens
  • To establish immunological profiles of adjuvants that work through different mechanisms, facilitating the identification of the most promising adjuvant-Mtb immunogen candidates for clinical development and potential immune correlates of protection.

Contact Information

Nancy Vazquez

Featured Research

NIAID’s TB Research

NIAID supports a comprehensive portfolio of research to better understand TB.

Read more about NIAID’s TB research
Content last reviewed on